Ciprofloxacin I.v. : Defining Its Role in Serious Infections

On the occasion of a symposium in Salzburg, an international team of clinicians and pharmacologists presented recent results in profile efficacy, safety and therapeutic use of the antibiotic substance Ciprofloxacin. Of special interest for clinicians will be the clinical outcome in patients with nosocomial pneumonia and other infections of the lower respiratory tract. Front Matter....Pages i-xii Effect of Quinolones Against Slowly Growing Bacteria....Pages 1-12 The Postantibiotic Effect of Ciprofloxacin....Pages 13-19 The Effects of Different Types of Antimicrobial Agents on Plasma Endotoxin Activity in Gram-Negative Bacterial Infection....Pages 21-38 Dose-Finding Investigations of Intravenous Ciprofloxacin in a Pharmacodynamic Model....Pages 39-48 The Relationship Between Ciprofloxacin Blood Concentrations, MIC Values, Bacterial Eradication, and Clinical Outcome in Patients with Nosocomial Pneumonia....Pages 49-61 Efficacy and Safety of Ciprofloxacin in Various Intravenous Dosages....Pages 63-73 Intravenous Ciprofloxacin Versus Imipenem/ Cilastatin in the Treatment of Severe Pneumonia....Pages 75-83 Conversion from Intravenous to Oral Ciprofloxacin: Observing the “Like-to-Like” Phenomenon....Pages 85-95 Therapeutic Use of Quinolones in Oncology....Pages 97-108 Ciprofloxacin in Neutropenic Host Infection....Pages 109-119 Intravenous Ciprofloxacin for the Treatment of Lower Respiratory Tract Infections: Preliminary Results....Pages 121-130 Integrated Safety Profile of Intravenous Ciprofloxacin....Pages 131-146